LIFE-U:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund (USD)

ETF | Others |

Last Closing

CAD 20.2

Change

-0.26 (-1.27)%

Market Cap

N/A

Volume

601.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

-0.29 (-1.07%)

CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

+0.01 (+0.02%)

CAD 5.38B
XEQT:CA iShares Core Equity Portfolio

+0.07 (+0.21%)

CAD 5.22B
PHYS-U:CA Sprott Physical Gold Trust

-0.13 (-0.65%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

+0.11 (+0.29%)

CAD 4.54B
HXT-U:CA Global X S&P/TSX 60 Index ETF

+0.44 (+0.96%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

-0.13 (-0.54%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

-0.07 (-0.68%)

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.14 (-0.62%)

CAD 2.78B
ZMMK:CA BMO Money Market Fund ETF Seri..

N/A

CAD 2.68B

ETFs Containing LIFE-U:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.70% 7% C- 17% F
Dividend Return 3.44% 64% D 53% F
Total Return 1.73% 8% B- 17% F
Trailing 12 Months  
Capital Gain 4.02% 17% F 23% F
Dividend Return 4.87% 69% C- 58% F
Total Return 8.88% 21% F 26% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.65% 17% F 22% F
Dividend Return -1.63% 16% F 15% F
Total Return 0.03% 18% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 6.06% 70% C- 86% B+
Risk Adjusted Return -26.88% 17% F 12% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.